Controlled release systems of angiogenic growth factors for cardiovascular diseases

By Esaki Jiro   Marui Akira   Tabata Yasuhiko   Komeda Masashi  

Expert Opinion on Drug Delivery, Vol. 4, Iss. 6, 2007-11 ,pp. : 635-649

Informa Healthcare

Access to resources Recommend Favorite

Critical factors in the design of growth factor releasing scaffolds for cartilage tissue engineering

By Sohier J   Moroni L   Blitterswijk C van   Groot K de   Bezemer JM  

Expert Opinion on Drug Delivery, Vol. 5, Iss. 5, 2008-05 ,pp. : 543-566

Informa Healthcare

Access to resources Recommend Favorite

Is immune-mediated heparin-induced thrombocytopenia less common with low-molecular-weight heparins, and should a low-molecular-weight heparin be used in a patient who develops this complication with standard, unfractionated heparin? - Molecular mechanisms and therapeutic utility

By Howe A.M.   Allerman A.A.  

Disease Management and Clinical Outcomes, Vol. 1, Iss. 6, 1998-11 ,pp. : 207-210

Elsevier

Access to resources Recommend Favorite

Chronopharmacology and controlled drug release

By Lemmer Björn  

Expert Opinion on Drug Delivery, Vol. 2, Iss. 4, 2005-07 ,pp. : 667-681

Informa Healthcare

Access to resources Recommend Favorite

Controlled-release microchips

By Sharma Sadhana   Nijdam A Jasper   Sinha Piyush M   Walczak Robbie J   Liu Xuewu   Cheng Mark M-C   Ferrari Mauro  

Expert Opinion on Drug Delivery, Vol. 3, Iss. 3, 2006-05 ,pp. : 379-394

Informa Healthcare

Access to resources Recommend Favorite